Document text
Principal Investigator: JENNIFER A DOUDNA
Organization: J. DAVID GLADSTONE INSTITUTES
Fiscal Year: 2021
Award: $519,750
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
We aim to determine the molecular basis for SARS-CoV-2 viral packaging and to develop a screening strategy
to identify inhibitors of this key step in the coronavirus infection cycle. Selective packaging of the viral genome,
over more abundant transcripts, involves specific interactions between an RNA packaging signal, viral structural
proteins and possibly other factors. Inhibition of this process would block formation of infectious virions and
thereby contribute to a therapeutic regimen that would prevent or treat infection. Building on our laboratory’s
extensive expertise in RNA biochemistry and virus-like particle research, we propose to determine the functional
SARS-CoV-2 packaging signal and to develop a robust small molecule-based assay for SARS-CoV-2 packaging
inhibition.
To determine the components of the SARS-CoV-2 packaging mechanism, we will generate virus-like particles
(VLPs) that contain the structural proteins of the virus but not the viral genome. The absence of the genome
renders these VLPs non-infectious and therefore safe to work with. Methods for generating these VLPs derive
from published research with other coronaviruses as well as our own lab’s experience working with influenza
and HIV VLPs. SARS-CoV-2 VLPs will be produced by co-expressing the viral spike (S), envelope (E),
membrane (M) and nucleocapsid (N) proteins. RNA molecules containing the packaging signal can be packaged
into these VLPs and delivered into receiver cells, providing an assay for packaging signal detection. In parallel,
this approach will be used to establish a screening assay to identify viral packaging inhibitors. These two aims
are independent, yet the results of each workstream will inform both the fundamental and applied aspects of the
project.
Our long-term objective is to develop a small molecule inhibitor of SARS-CoV-2 viral packaging. This approach
has the following advantages: 1) we will naturally detect nucleocapsid inhibitors, which can be potent antiviral
drugs as shown for HIV and other viruses due to strict constraints on nucleocapsid function; 2) our approach
targets a step in the viral infection cycle that is not currently the focus of major therapeutic discovery efforts,
enhancing the opportunity to find a new and/or complementary antiviral strategy; and 3) our screening approach
does not require live virus and can be executed safely in most high-throughput screening facilities.
The research proposed here will enable the development of new antiviral strategies for treating coronaviruses.
SARS-CoV-2 is the third betacoronavirus to trigger a zoonotic outbreak in the last 18 years and estimates
suggest that ~5000 related viruses are circulating within bat populations around the world. Our proposal targets
a critical yet relatively understudied step of the coronavirus life cycle that is a promising target of selective small-
molecule inhibition. The results of this work will inform and enable other viral inhibition efforts and provide a basis
for future high-throughput drug discovery initiatives.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity Chromatography><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bats><Binding><Binding Proteins><Bio-Informatics><Bioassay><Biochemical><Bioinformatics><Biologic Assays><Biological Assay><COVID therapy><COVID treatment><COVID-19 assay><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19 assay><COVID19 therapy><COVID19 treatment><COVID19 virus><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Capsid><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cells><Chiroptera><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><CoV-2><CoV2><Combined Modality Therapy><Complement><Complement Proteins><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Data><Detection><Development><Disease><Disease Outbreaks><Disorder><Drug Targeting><Drug resistance><Enterovirus 71><Envelope Protein><Foundations><Future><Gene Delivery><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genome><Goals><Green Fluorescent Proteins><Grippe><HIV><High Throughput Assay><Human Immunodeficiency Viruses><Infection><Influenza><Intracellular Communication and Signaling><Knock-out><Knockout><LAV-HTLV-III><Laboratories><Libraries><Life Cycle><Life Cycle Stages><Ligand Binding Protein><Ligand Binding Protein Gene><Location><Lymphadenopathy-Associated Virus><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mediating><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Methods><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Molecular><Molecular Interaction><Mouse Hepatitis Virus><Multimodal Therapy><Multimodal Treatment><Murine Gastroenteritis Virus><Murine hepatitis virus><Mutation><Non-Polyadenylated RNA><Nucleic Acid Biochemistry, RNA - Ribonucleic Acid><Nucleocapsid><Nucleocapsid Proteins><ORFs><Open Reading Frames><Outbreaks><Population><Process><Production><Protein Binding><Protein Coding Region><Proteins><Proteomics><Publishing><RNA><RNA Biochemistry><RNA Gene Products><RNA Nucleic Acid Biochemistry><RNA Viruses><Regimen><Reporter><Research><Ribonucleic Acid><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 assay><SARS-CoV-2 inhibitor><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Structural Protein><Structure><Surface Proteins><Technology><Test Result><Testing><Therapeutic><Transcript><Transfection><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Genome><Viral Packaging><Viral Pathogenesis><Viral Proteins><Viral Structural Proteins><Virion><Virus><Virus Diseases><Virus Packagings><Virus Particle><Virus-HIV><Virus-like particle><Work><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><affinity purification><anti-viral agents><anti-viral drugs><anti-virals><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biological signal transduction><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><bound protein><cell culture><combination therapy><combined modality treatment><combined treatment><corona virus><coronavirus disease 2019 assay><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease therapy><coronavirus disease treatment><coronavirus therapy><coronavirus treatment><developmental><drug development><drug discovery><drug resistant><effective therapy><effective treatment><env Antigens><env Gene Products><env Polyproteins><env Protein><experience><genome mutation><hCoV19><high throughput screening><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibitor><inhibitor/antagonist><insight><lab experience><lab training><laboratory experience><laboratory training><lead candidate><life course><multi-modal therapy><multi-modal treatment><nCoV2><prevent><preventing><resistance to Drug><resistant to Drug><screening><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><small molecule><small molecule inhibitor><social role><stem><therapeutic target><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral RNA><viral detection><viral infection><viral resistance><virus RNA><virus detection><virus genome><virus infection><virus pathogenesis><virus protein><virus resistance><virus-induced disease><virus-like nanoparticles><viruslike particle><β CoV><β coronavirus><βCoV>